Optimizing tolerability of TKI therapy in CML
- PMID: 24578491
- DOI: 10.1182/blood-2014-01-546705
Optimizing tolerability of TKI therapy in CML
Comment on
-
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17. Blood. 2014. PMID: 24345751 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical